Received Mar 18, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
The patient missed third dose of Vivotif and took it one day later; Case reference number US-BN-2025-000165 is a spontaneous case initially received from pharmacist via Communication (reference number: USBAV25-0194) on 27-Jan-2025 and concerns a female patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On 21-Jan-2025, the patient took the first dose of Vivotif vaccine (batch number: unknown), at an unknown dose, orally, for unknown indication. On 23-Jan-2025, two days after the first dose, the patient took the second dose of Vivotif vaccine (batch number: unknown), at an unknown dose, orally. On 26-Jan-2025, five days after the first dose, the patient took the third dose of Vivotif vaccine (batch number: unknown), at an unknown dose, route or site of administration. As reported, the patient missed third dose of Vivotif and took it one day later (explicitly coded as 'inappropriate schedule of vaccine administered'). At the time of initial report, it was unknown if the patient experienced any adverse events due to Vivotif. No further information was provided.; Reporter's Comments: A female patient of unspecified age missed third dose of Vivotif and took it one day later, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A female patient of unspecified age missed third dose of Vivotif and took it one day later, which is considered as inappropriate schedule of vaccine administered. It was unknown if the patient experienced any adverse events due to Vivotif. Inappropriate schedule of product administration is considered as listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Comments: None